CAR-T cell therapy in India: who it suits, and cost

What it is: Your own T-cells, genetically modified to attack your cancer
Used for: Certain leukaemias, lymphomas and myeloma, usually after relapse
Not for: Solid tumours such as breast, lung or colon cancer
One infusion: A single dose, after weeks of manufacturing
Main risks: Cytokine release syndrome and neurological effects, both time-critical
Cost in India: Far below Western prices, largely due to indigenous products

How it works

Your T-cells are the part of your immune system that kills infected and abnormal cells. They are good at it, but cancer cells often lack the markers T-cells look for, so they go unrecognised. CAR-T solves that by giving your T-cells a new receptor that recognises a protein on your cancer cells specifically.

The process is genuine cell engineering rather than a drug. Your blood is collected, the T-cells separated out, and in a laboratory a gene is inserted so they manufacture the new receptor. Those modified cells are then multiplied into many millions and returned to you as a single infusion. Once inside, they continue to multiply and hunt, which is why one dose can keep working for months or years. Some patients remain in remission long afterwards.

Who it is for

May be eligible

B-cell acute lymphoblastic leukaemia, particularly in younger patients
Diffuse large B-cell lymphoma and some other B-cell lymphomas
Multiple myeloma after several previous lines of treatment
Disease that has returned after chemotherapy or transplant
Patients well enough to tolerate an intensive few weeks

Not suitable

Solid tumours: breast, lung, colon, prostate and the rest
Cancers without a suitable target protein on their surface
Patients too unwell to withstand cytokine release syndrome
Active uncontrolled infection
Cases where standard treatment has not yet been tried

Please read the right-hand column carefully. CAR-T is discussed in the media as though it were a general cancer cure, and families sometimes travel hoping for it when it cannot apply. It is a treatment for specific blood cancers with a specific target. Anyone offering CAR-T for a solid tumour outside a formal clinical trial is not being straight with you.

What the process involves

Eligibility assessment. Your diagnosis, previous treatment, organ function and general fitness are reviewed against the criteria.
Collection (apheresis). Blood is drawn through a machine that separates out T-cells and returns the rest. Several hours, no anaesthetic.
Manufacturing. Two to four weeks in the laboratory while your cells are modified and multiplied. Bridging treatment may hold the cancer in check meanwhile.
Lymphodepleting chemotherapy. A short course a few days beforehand, making room for the new cells to expand.
Infusion. The cells are returned through a drip. The infusion itself is quick and undramatic.
Close monitoring. Several weeks nearby, watching for cytokine release syndrome and neurological effects, which need immediate treatment.

The risks, stated plainly

Cytokine release syndrome is the most characteristic. As the engineered cells activate and attack, they release signalling molecules that can cause high fever, low blood pressure and breathing difficulty. It ranges from mild and flu-like to severe enough to need intensive care. It is well recognised and treatable with specific drugs, but treatment must be immediate, which is why you stay close to the hospital.

Neurological effects can also occur: confusion, difficulty finding words, tremor, and rarely seizures. These are usually temporary and resolve with treatment, though they are frightening to witness. Staff will check you repeatedly for these signs, including asking you simple questions and to write a sentence, and this is routine rather than a sign anything is wrong.

Low blood counts and infection risk follow for weeks or months, since the treatment removes normal B-cells along with cancerous ones. Some patients need immunoglobulin replacement afterwards.

This is why CAR-T requires an experienced centre with intensive care immediately available, and why a companion needs to stay with you throughout. It is not a treatment to have far from support.

Cost, and why India is genuinely different here

CAR-T is among the most expensive treatments in medicine. In the United States and Europe the commercial products have prices that put them out of reach for most families paying privately, and even insured patients face significant barriers.

India developed its own indigenous CAR-T product, approved for use there, at a fraction of Western prices. This is the reason CAR-T appears on an India medical travel site at all: for some families it is the difference between a treatment that exists in theory and one they can actually access.

Be realistic about the total, though. The cost is not only the cell product: it includes apheresis, manufacturing, bridging treatment, lymphodepleting chemotherapy, the infusion, and weeks of close monitoring with intensive care available. Accommodation for a long stay adds to it. You receive a written estimate covering the whole pathway before you commit, with no fee to us built in; the hospital pays us, so your bill is never marked up.

How long you will need to be in India

Plan for months rather than weeks. Assessment and collection, then two to four weeks of manufacturing, then the infusion, then several weeks of close monitoring before you can safely travel home. Your team will also want follow-up arrangements in place for after you return. A companion must be with you for the whole period.

Questions patients ask

Can CAR-T treat my solid tumour?

Not currently, outside clinical trials. Approved CAR-T therapies treat certain B-cell blood cancers and myeloma. Solid tumours present obstacles that researchers are still working on, including the lack of a clean target protein and the difficulty of getting cells into a tumour mass. Anyone offering commercial CAR-T for breast, lung or colon cancer is misrepresenting it.

Is it a cure?

For some patients it produces remissions that have now lasted many years, which is remarkable in cancers that had relapsed after everything else. For others the cancer returns. It is a genuine and sometimes dramatic advance, not a guarantee, and your specialist can give a realistic expectation for your specific disease and situation.

How is it different from a bone marrow transplant?

A transplant replaces your blood-forming system, often using a donor's stem cells, and carries the risk of graft-versus-host disease. CAR-T uses your own cells, modified to attack the cancer, with no donor and no graft-versus-host disease. Its characteristic risk is cytokine release syndrome instead. They are sometimes used in sequence.

What is cytokine release syndrome?

An inflammatory reaction as the engineered cells activate and attack the cancer, causing fever, low blood pressure and sometimes breathing difficulty. It ranges from mild to severe. It is expected, well recognised and treatable with specific drugs, provided treatment is immediate, which is why you stay close to the hospital for weeks afterwards.

Do I need a donor?

No. CAR-T uses your own T-cells, which is one of its advantages over a donor transplant. There is no matching process and no waiting for a donor, and no risk of graft-versus-host disease. The waiting period is instead the two to four weeks your cells spend being manufactured.

Why is it so much cheaper in India?

India developed and approved its own indigenous CAR-T product rather than relying solely on imported commercial therapies, and manufacturing domestically removes much of the cost. For families who could not access CAR-T at Western prices, this is the practical difference. Ask which product is proposed and confirm it is an approved therapy rather than an experimental offering.

What reports should I send?

Your exact diagnosis including subtype, bone marrow biopsy and any cytogenetic or molecular results, a full history of treatments already given and how the cancer responded, recent blood counts, recent scans, and details of any previous transplant. Eligibility depends heavily on treatment history, so completeness matters.